Hematologic Malignancy
Primary Central Nervous System Lymphoma
CI-CAN-00003730PCNSLExplore in graph →
Hematologic55 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003730PCNSLExplore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07764601 | R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma(RM-MA-PD1) | not yet recruiting | N/A | 58 | WEI XUOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07710131 | Neurocognitive Assessment CNSL and LGG | not yet recruiting | N/A | 36 | Dana-Farber Cancer InstituteOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07406230 |
| Methotrexate Early Toxicity Monitoring(METoxiM) |
| not yet recruiting |
| N/A |
| 50 |
| Assistance Publique Hopitaux De MarseilleOTHER |
| 1 |
| Feb 12, 2026 |
| clinicaltrials |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | not yet recruiting | N/A | 30 | Zhengzhou UniversityOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL(VPX) | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05036564 | Diagnosis; Objective RespOnse; THErApy(DOROTHEA) | recruiting | N/A | 70 | IRCCS San RaffaeleOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | recruiting | N/A | 41 | FengYan JinOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | recruiting | N/A | 44 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06445257 | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL | unknown | N/A | 30 | Huai'an First People's HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | N/A | 1 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials